<DOC>
	<DOCNO>NCT01139723</DOCNO>
	<brief_summary>This Phase I , first-in-human , open label , dose-escalation study MINT1526A administer alone combination bevacizumab IV infusion every 3 week patient advance solid tumor standard therapy either exist proven ineffective intolerable .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics MINT1526A , Administered Intravenously As Single Agent Combination With Bevacizumab Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically document , incurable , metastatic solid malignancy progress failed respond regimen therapy know provide clinical benefit Adequate hematologic end organ function Evaluable disease measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) 1.0 ; prostate cancer patient nonevaluable nonmeasurable disease increase prostatespecific antigen ( PSA ) ; ovarian cancer patient nonevaluable nonmeasurable disease increase cancer antigen 125 ( CA125 ) For female patient childbearing potential male patient partner childbearing potential , agreement use effective form contraception continue use 6 month discontinuation study Any anticancer therapy , include chemotherapy , hormonal therapy , radiotherapy within specify timeframe prior initiation study treatment . Leptomeningeal disease Active infection require intravenous antibiotic Active autoimmune disease control nonsteroidal antiinflammatory drug , inhale corticosteroid , prednisone Bisphosphonate therapy symptomatic hypercalcemia Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis Known primary central nervous system ( CNS ) malignancy untreated active CNS metastasis Pregnancy , lactation , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>